News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Mario Occhipinti: Target approach in pleural mesothelioma
Photo from Mario Occhipinti/X
Aug 22, 2024, 04:27

Mario Occhipinti: Target approach in pleural mesothelioma

Mario Occhipinti shared on X:

“Happy to share our latest article review on target approach in pleural mesothelioma! Check it out!”

https://x.com/mocchipintimd/status/1825976449486172163?s=46

Unleashing precision: a review of targeted approaches in pleural mesothelioma

Authors: Mario Occhipinti, Marta Brambilla, Raimondo Di Liello, Paolo Ambrosini, Lorenzo Lobianco, Rita Leporati, Maria Salvarezza, Fabiana Vitiello, Silvia Marchesi, Sara Manglaviti, Teresa Beninato, Laura Mazzeo, Claudia Proto, Arsela Prelaj, Roberto Ferrara, Carminia Maria Della Corte, Giuseppe Lo Russo, Filippo de Braud, Monica Ganzinelli, Giuseppe Viscardi

https://x.com/mocchipintimd/status/1825976449486172163?s=46

Source: Mario Occhipinti/X

Mario Occhipinti is a medical oncologist at theIRCCS Foundation National Cancer Institute of Milan. He completed his residency from the Sapienza University of Rome. He is a part of the AIOM Young Committee.

Arsela Prelaj cancer Carminia Maria Della Corte Claudia Proto Fabiana Vitiello Filippo de Braud Giuseppe Lo Russo Giuseppe Viscardi Laura Mazzeo Lorenzo Lobianco Maria Salvarezza Mario Occhipinti Marta Brambilla mesothelioma Monica Ganzinelli OncoDaily Oncology Paolo Ambrosini Raimondo Di Liello Rita Leporati Roberto Ferrara Sara Manglaviti Silvia Marchesi Teresa Beninato
Special Coverage
Science
Dec 21, 2024, 09:06
Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial
Blog
Dec 21, 2024, 09:00
Miriam Mutebi: Does Nipple and Areola Size Matter?
Science
Dec 21, 2024, 08:51
Wafik S. El-Deiry: Our recent review on Targeting the SMURF2-HIF1α axis
Science
Dec 21, 2024, 08:48
Oncology Brothers: Another ALK inhibitor gets FDA approval
Science
Dec 21, 2024, 08:42
Eric K. Singhi: Decoding clinical trial jargon
Science
Dec 21, 2024, 08:37
Gustavo Viani: The Role of Radiotherapy on the management of HCC
Science
Dec 21, 2024, 08:29
Bishal Gyawali: The case of cancer drug Xtandi
Blog
Dec 21, 2024, 08:18
Sami (Papacek) Mansfield: Why is muscle health so important among cancer survivers?
Career
Dec 21, 2024, 08:12
Rishabh Singh: Honored to receive the Mary Draeger Schultz Scholarship 2024
Science
Dec 21, 2024, 07:56
Predictors of Discharge With Supplemental Oxygen After Lobectomy for Lung Cancer
Career
Dec 21, 2024, 07:45
OncoInfluencers to Follow on Social Media: Dr. Liang Cheng
Insight
Dec 21, 2024, 07:31
Update on U.S. regulatory review of subcutaneous amivantamab for EGFR + lung cancer